Can Compass Pathways' Stock Gain 458% Like Wall Street Is Expecting?
While Compass Pathways' (NASDAQ: CMPS) stock is near $8, the analysts on Wall Street are figuring, on average, that its shares will explode by 458% to reach around $42.30 within the next 12 months.
There's no doubt that the psychedelic therapy developer has some promising projects in the making. But could it possibly be true that the company will multiply in value in such a short period?
Right off the bat, Wall Street's estimate bears quite a bit of skepticism. Compass is a pre-revenue biotech company that's nowhere close to commercializing its flagship therapy, COMP360, which is being investigated for treatment-resistant depression (TRD), among a smattering of other potential indications like post-traumatic stress disorder (PTSD).
Source Fool.com
